Prognostic Factors in Non-malignant and Non-cirrhotic Patients with Portal Cavernoma: an 8-year Retrospective Single-center Study

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2013 Nov 22

PMID 24259977

Citations 5

Authors

Xing-Shun Qi

Ming Bai

Chuang-Ye He

Zhan-Xin Yin

Wen-Gang Guo

Jing Niu

Fei-Fei Wu

Guo-Hong Han

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the outcome of non-malignant and non-cirrhotic patients with portal cavernoma and to determine the predictors for survival.

Methods: Between July 2002 and June 2010, we retrospectively enrolled all consecutive patients admitted to our department with a diagnosis of portal cavernoma without abdominal malignancy or liver cirrhosis. The primary endpoint of this observational study was death and cause of death. Independent predictors of survival were identified using the Cox regression model.

Results: A total of 64 patients were enrolled in the study. During a mean follow-up period of 18 ± 2.41 mo, 7 patients died. Causes of death were pulmonary embolism (n = 1), acute leukemia (n = 1), massive esophageal variceal hemorrhage (n = 1), progressive liver failure (n = 2), severe systemic infection secondary to multiple liver abscesses (n = 1) and accident (n = 1). The cumulative 6-, 12- and 36-mo survival rates were 94.9%, 86% and 86%, respectively. Multivariate Cox regression analysis demonstrated that the presence of ascites (HR = 10.729, 95%CI: 1.209-95.183, P = 0.033) and elevated white blood cell count (HR = 1.072, 95%CI: 1.014-1.133, P = 0.015) were independent prognostic factors of non-malignant and non-cirrhotic patients with portal cavernoma. The cumulative 6-, 12- and 36-mo survival rates were significantly different between patients with and without ascites (90%, 61.5% and 61.5% vs 97.3%, 97.3% and 97.3%, respectively, P = 0.0008).

Conclusion: The presence of ascites and elevated white blood cell count were significantly associated with poor prognosis in non-malignant and non-cirrhotic patients with portal cavernoma.

Citing Articles

Natural History and Outcomes of Cavernous Transformation of the Portal Vein in Cirrhosis.

Attanasi M, Bou Daher H, Rockey D Dig Dis Sci. 2023; 68(8):3458-3466.

PMID: 37349605 DOI: 10.1007/s10620-023-07993-3.

Collateral circulation caused by end-stage hepatic alveolar echinococcosis.

Jiang T, Aji T, Ran B, Guo Q, Zhang R, Ahan A BMC Infect Dis. 2023; 23(1):322.

PMID: 37189056 PMC: 10184362. DOI: 10.1186/s12879-022-07970-7.

Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein.

Wei B, Huang Z, Tang C Front Med (Lausanne). 2022; 9:853138.

PMID: 35402447 PMC: 8987530. DOI: 10.3389/fmed.2022.853138.

An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty.

Qi X, Guo X Arch Med Sci. 2016; 12(6):1381-1383.

PMID: 27904533 PMC: 5108399. DOI: 10.5114/aoms.2016.62921.

Outcome of the Pediatric Patients with Portal Cavernoma: The Retrospective Study for 10 Years Focusing on Recurrent Variceal Bleeding.

Guo H, Hao F, Guo C, Yu Y Gastroenterol Res Pract. 2016; 2016:7953870.

PMID: 26949386 PMC: 4754495. DOI: 10.1155/2016/7953870.

References

Idezuki Y . General rules for recording endoscopic findings of esophagogastric varices (1991). Japanese Society for Portal Hypertension. World J Surg. 1995; 19(3):420-2; discussion 423. DOI: 10.1007/BF00299178. View

Ohnishi K, Okuda K, Ohtsuki T, Nakayama T, Hiyama Y, Iwama S . Formation of hilar collaterals or cavernous transformation after portal vein obstruction by hepatocellular carcinoma. Observations in ten patients. Gastroenterology. 1984; 87(5):1150-3. View

Qi X, Han G, Wang J, Wu K, Fan D . Degree of portal vein thrombosis. Hepatology. 2009; 51(3):1089-90. DOI: 10.1002/hep.23397. View

De Franchis R . Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53(4):762-8. DOI: 10.1016/j.jhep.2010.06.004. View

Moore K, Wong F, Gines P, Bernardi M, Ochs A, Salerno F . The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003; 38(1):258-66. DOI: 10.1053/jhep.2003.50315. View

Ponziani F, Zocco M, Campanale C, Rinninella E, Tortora A, Di Maurizio L . Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol. 2010; 16(2):143-55. PMC: 2806552. DOI: 10.3748/wjg.v16.i2.143. View

Qi X, De Stefano V, Wang J, Bai M, Yang Z, Han G . Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol. 2012; 28(3):432-42. DOI: 10.1111/jgh.12085. View

Qi X, Yang Z, Bai M, Shi X, Han G, Fan D . Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther. 2011; 33(10):1087-103. DOI: 10.1111/j.1365-2036.2011.04627.x. View

WEBB L, Sherlock S . The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med. 1979; 48(192):627-39. View

10.

DeLeve L, Valla D, Garcia-Tsao G . Vascular disorders of the liver. Hepatology. 2009; 49(5):1729-64. PMC: 6697263. DOI: 10.1002/hep.22772. View

11.

Qi X, Han G, Yin Z, He C, Wang J, Guo W . Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci. 2011; 57(4):1072-82. DOI: 10.1007/s10620-011-1975-5. View

12.

Qi X, Han G, He C, Yin Z, Guo W, Niu J . CT features of non-malignant portal vein thrombosis: a pictorial review. Clin Res Hepatol Gastroenterol. 2012; 36(6):561-8. DOI: 10.1016/j.clinre.2012.05.021. View

13.

Rajani R, Bjornsson E, Bergquist A, Danielsson A, Gustavsson A, Grip O . The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010; 32(9):1154-62. DOI: 10.1111/j.1365-2036.2010.04454.x. View

14.

Han G, Qi X, He C, Yin Z, Wang J, Xia J . Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2010; 54(1):78-88. DOI: 10.1016/j.jhep.2010.06.029. View

15.

De Stefano V, Martinelli I . Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010; 5(6):487-94. DOI: 10.1007/s11739-010-0413-6. View

16.

Qi X, Zhang C, Han G, Zhang W, He C, Yin Z . Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study. J Gastroenterol Hepatol. 2011; 27(6):1036-43. DOI: 10.1111/j.1440-1746.2011.07040.x. View

17.

Amitrano L, Guardascione M, Scaglione M, Pezzullo L, Sangiuliano N, Armellino M . Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007; 102(11):2464-70. DOI: 10.1111/j.1572-0241.2007.01477.x. View

18.

Orr D, Harrison P, Devlin J, Karani J, Kane P, Heaton N . Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2006; 5(1):80-6. DOI: 10.1016/j.cgh.2006.09.030. View

19.

Janssen H, Wijnhoud A, Haagsma E, van Uum S, van Nieuwkerk C, Adang R . Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001; 49(5):720-4. PMC: 1728504. DOI: 10.1136/gut.49.5.720. View

20.

Qi X, He C, Han G, Yin Z, Wu F, Zhang Q . Prevalence of paroxysmal nocturnal hemoglobinuria in Chinese patients with Budd-Chiari syndrome or portal vein thrombosis. J Gastroenterol Hepatol. 2012; 28(1):148-52. DOI: 10.1111/j.1440-1746.2012.07282.x. View